✦ LIBER ✦

Prostate-specific antigen and detection of prostate cancer: What have we learned and what should we recommend for screening?

✍ Scribed by Christopher L. Amling

Book ID: 107531928
Publisher: Springer
Year: 2006
Tongue: English
Weight: 287 KB
Volume: 7
Category: Article
ISSN: 1527-2729
DOI: 10.1007/s11864-006-0001-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Screening for prostate cancer with serum

Screening for prostate cancer with serum prostate-specific antigen : What should we recommend while waiting for randomized clinical trial results?

✍ John W. Davis 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 32 KB

Prostate Cancer Screening: What We Have

Prostate Cancer Screening: What We Have Learned from the PLCO and ERSPC Trials

✍ Jeffrey La Rochelle; Christopher L. Amling 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 93 KB

I–125 interstitial implantation for pros

I–125 interstitial implantation for prostate cancer. What have we learned 10 years later?

✍ Deborah A. Kuban; Anas M. El-Mahdi; Paul F. Schellhammer 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 505 KB

Quality of life after breast cancer surg

Quality of life after breast cancer surgery: What have we learned and where should we go next?

✍ Barbara A. Pockaj; Amy C. Degnim; Judy C. Boughey; Richard J. Gray; Sarah A. McL 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 109 KB

Recurrence-free survival rates after ext

Recurrence-free survival rates after external-beam radiotherapy for patients with clinical T1–T3 prostate carcinoma in the prostate-specific antigen era : What should we expect?

✍ Deepak Khuntia; Chandana A. Reddy; Arul Mahadevan; Eric A. Klein; Patrick A. Kup 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 174 KB

## Abstract ## BACKGROUND The objective of the current study was to report biochemical recurrence–free survival (bRFS) rates among men with T1–T3 prostate carcinoma who were treated with external‐beam radiotherapy (RT) at the Cleveland Clinic Foundation (Cleveland, OH). ## METHODS In total, 1352

Molecular forms of prostate-specific ant

Molecular forms of prostate-specific antigen in serum with concentrations of total prostate-specific antigen <4 μg/L: Are they useful tools for early detection and screening of prostate cancer?

✍ Klaus Jung; Carsten Stephan; Ulrike Elgeti; Michael Lein; Brigitte Brux; Glen Kr 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 French ⚖ 149 KB 👁 1 views

Molecular forms of prostate-specific antigen (PSA) improve the differentiation between benign prostatic hyperplasia (BPH) and prostate cancer (PCa) in men with total PSA concentrations between 4 and 10 microg/l. To evaluate the diagnostic utility of free PSA (fPSA) and complexed PSA forms for identi